# A Study of a Personalized Neoantigen Cancer Vaccine

> **NCT03639714** · PHASE1,PHASE2 · COMPLETED · sponsor: **Gritstone bio, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Colorectal Cancer
- Gastroesophageal Adenocarcinoma
- Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** GRT-C901
- **BIOLOGICAL:** GRT-R902
- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** ipilimumab

## Key facts

- **NCT ID:** NCT03639714
- **Lead sponsor:** Gritstone bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-13
- **Primary completion:** 2022-11-10
- **Final completion:** 2022-11-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639714, "A Study of a Personalized Neoantigen Cancer Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03639714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*